title: Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
authors.forename: P
authors.initials: P
authors.lastname: Darmon
authors.forename: C
authors.initials: C
authors.lastname: Curtillet
authors.forename: S
authors.initials: S
authors.lastname: Boullu
authors.forename: A
authors.initials: A
authors.lastname: Laugier
authors.forename: A
authors.initials: A
authors.lastname: Dutour
authors.forename: C
authors.initials: C
authors.lastname: Oliver
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D020405:Dermis / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D061268:Insulin Lispro; D007333:Insulin Resistance; D008875:Middle Aged; D009765:Obesity
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro